Sanofi, Cipla ink distribution pact to expand CNS portfolio reach in India

27 Mar 2024 , 11:10 AM

On March 26, Sanofi India Limited, Sanofi Healthcare India Private Limited, and Cipla Limited announced an exclusive distribution and marketing agreement for the sale and promotion of Sanofi India’s Central Nervous System (CNS) product range in India, according to an exchange filing.

As part of this cooperation, Cipla will manage distribution of Sanofi India’s six CNS products, including the industry-leading anti-epileptic medication Frisium®.

According to the joint statement, Cipla will use its expertise and a strong India-wide network of distributors, institutions, and market outreach activities to increase patient access to these therapies. Meanwhile, Sanofi India will continue to own, import, and manufacture its complete CNS product portfolio at sites in India and elsewhere.

Rodolfo Hrosz, Managing Director of Sanofi India Limited, emphasized that their CNS products hold leading positions within their respective categories. These established brands currently enhance the lives of numerous patients in urban areas nationwide. Leveraging Cipla’s extensive presence will facilitate the expansion of this portfolio’s accessibility to healthcare professionals and patients throughout India.

Achin Gupta, CEO of One India Business at Cipla Limited, emphasized that improving access to top-notch treatments aligns with their core mission of ‘Caring for Life’. He expressed satisfaction in partnering with Sanofi India to broaden access to effective and high-quality therapeutic solutions in CNS, aiming to benefit patients nationwide. Recognizing the complexity of the Central Nervous System domain in medicine, Gupta sees this collaboration as a notable stride towards fulfilling the needs of underserved patients.

At around 11.04 AM, Sanofi India was trading 5.26% higher at ₹8,113.90 per piece, against the previous close of ₹7,708.30 on NSE. The counter touched an intraday high of ₹8,125.05.

For feedback and suggestions, write to us at [e-mail]